RapamycinEvidence & Dosage
mTOR inhibition, longevity studies, off‑label dosing, and safety.
Evidence at a glance
- Total studies
- 910
- With abstract
- 50
- Meta / Systematic / RCT
- 121
- Highly cited
- 50
- Publication years
- 1991–2026
Rapamycin in the context of Longevity
This topic is part of our "Longevity" world. There you'll find methodology, evidence and the highest-impact levers — plus the order in which they sensibly build on each other.
Go to LongevityTop studies on Rapamycin
Ranked by influential-citation count and publication year.
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.
Lancet2007n=18Meta-Analysis200 influential citations<h4>Background</h4>Whether the two drug-eluting stents approved by the US Food and Drug Administration-a sirolimus-eluting stent and a paclitaxel-eluting stent-are associated with increased risks of death, myocardial infarction, or stent…
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
N Engl J Med2007n=495Meta-Analysis200 influential citations<h4>Background</h4>The long-term effects of treatment with sirolimus-eluting stents, as compared with bare-metal stents, have not been established.<h4>Methods</h4>We performed an analysis of individual data on 4958 patients enrolled in 14…
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
Current Biology2004191 influential citationsThe mammalian TOR (mTOR) pathway integrates nutrient- and growth factor-derived signals to regulate growth, the process whereby cells accumulate mass and increase in size. mTOR is a large protein kinase and the target of rapamycin, an…
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.
Molecules and Cells2002152 influential citationsThe target of rapamycin (TOR) proteins in Saccharomyces cerevisiae, TOR1 and TOR2, redundantly regulate growth in a rapamycin-sensitive manner. TOR2 additionally regulates polarization of the actin cytoskeleton in a rapamycin-insensitive…
Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.
J Am Coll Cardiol2015n=52,158Meta-Analysis144 influential citations<h4>Background</h4>Previous meta-analyses have investigated the relative safety and efficacy profiles of different types of drug-eluting stents (DES) and bare-metal stents (BMS); however, most prior trials in these meta-analyses reported…
Finding: Late target-vessel revascularization was reduced with all drug-eluting stents compared with bare-metal stents.
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.
Molecules and Cells2006131 influential citationsThe drug rapamycin has important uses in oncology, cardiology, and transplantation medicine, but its clinically relevant molecular effects are not understood. When bound to FKBP12, rapamycin interacts with and inhibits the kinase activity…
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
Lancet2004n=5,103Meta-Analysis127 influential citations<h4>Background</h4>Drug-eluting stents (DES) are associated with lower restenosis rates than bare-metal stents (BMS), but the benefits and safety of the new devices have not been systematically quantified across different trials. We…
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Transplantation2005n=33,249Meta-Analysis125 influential citations<h4>Background</h4>Immunosuppressive drug therapy has been identified as one etiological factor in the increased incidence of and deaths from malignancies in renal transplant recipients. In animal models, calcineurin inhibitors have a…
Finding: In the Cox regression model, sirolimus/everolimus immunosuppression was linked to a reduced risk of any de novo cancer.
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Nature Cell Biology2004114 influential citationsThe target of rapamycin (TOR) is a highly conserved protein kinase and a central controller of cell growth. In budding yeast, TOR is found in structurally and functionally distinct protein complexes: TORC1 and TORC2. A mammalian…
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*
Journal of Biological Chemistry2009104 influential citationsThe mammalian target of rapamycin (mTOR) kinase is the catalytic subunit of two functionally distinct complexes, mTORC1 and mTORC2, that coordinately promote cell growth, proliferation, and survival. Rapamycin is a potent allosteric mTORC1…
Frequently asked
What dosage was studied?
Are there safety considerations for Rapamycin?
Related articles
Peter Attia's “Outlive”: the key takeaways for longevity
Structured summary of “Outlive”: ApoB instead of LDL, Centenarian Olympics, insulin sensitivity, sleep, and the Rapamycin question — soberly classified.
Rapamycin for Longevity: What Animal Data Show and What Is Missing in Humans
Rapamycin sounds promising, but the human data for longevity are thin. Here we separate animal studies, off-label practice, and open safety questions cleanly.
More topics in Longevity
Zone 2 Training
Low-intensity cardio — mitochondrial biogenesis, a longevity foundation.
AMPK Activators
Berberine, alpha‑lipoic acid, energetic stress, and glucose modulation.
ApoB
A better cardiovascular risk metric than LDL-C — modern lipidology.
Autophagy
Cellular self-clearance — fasting, exercise, spermidine as triggers.
Berberin
Glucose, lipids, AMPK and GI tolerability data
Biological Age
GrimAge, PhenoAge, DunedinPACE — what epigenetic clocks measure.
Caloric Restriction
CR mimetics, lifespan research, and NHP studies.
Cancer Screening
Recommendations, overdiagnosis, Galleri tests, whole-body MRI (a critical look).
Cellular Senescence
"Zombie cells," SASP, senolytic approaches.
Collagen
Skin, joints, tendons — evidence favors hydrolysate plus vitamin C.
Dementia Prevention
Lifestyle factors: exercise, sleep, hearing health, vascular health.
DEXA Bone Density
DEXA scan for bone + body composition — the trend matters more than a single value.
Epigenetic Clocks
Horvath, GrimAge, PhenoAge — what they measure and what they don't.
Epigenetics
DNA methylation, histone modifications, environmental influences on gene expression.
Exosomes
Cell-to-cell communication, regenerative applications, an early research field.
Genetic Tests
Variants, pharmacogenomics, limitations — methylation, MTHFR myths.
Glucosamine
Joints, UK Biobank mortality study, sulfate vs HCl forms.
Glycine
Methylation, collagen synthesis, lifespan signals in animal models.
Grip Strength
A strong mortality predictor — easy to measure, trainable.
Hallmarks of Aging
Genomic instability, telomere shortening, epigenetic alterations, and more.
Related topics from other worlds
TSH
The sensitive first-line marker — read alongside fT3/fT4 and symptoms.
Blood-Brain Barrier
Selective permeability, substance passage, inflammation-driven leakiness.
Dopamine Detox
A popular trend without strong scientific backing — what still holds up.
L-Tyrosine
Dopamine precursor, stress performance and sleep deprivation
Neurons
Structure, axon, dendrites, action potentials — the basics of neural processing.
Pomodoro
25-minute focus blocks with micro-breaks — a time-management classic.